The life-threatening complications of dermatologic therapies

Clinics in Dermatology

Volumn 23, Issue 2, 2005, Pages 182-192

  Orion, Edith ^a   Matz, Hagit ^a,b   Wolf, Ronni ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CHLOROQUINE; CYCLOSPORIN; CYTOTOXIC AGENT; DAPSONE; DIAZEPAM; DISULFIRAM; ETANERCEPT; ETRETIN; FLUCONAZOLE; GRISEOFULVIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISOTRETINOIN; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; METHOTREXATE; METRONIDAZOLE; PYRROLE DERIVATIVE; RETINOID; STEROID; TERBINAFINE; UNINDEXED DRUG; VALACICLOVIR;

ACUTE PANCREATITIS; AGITATION; AGRANULOCYTOSIS; ALLERGY; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARRHYTHMOGENESIS; ARTICLE; ASTHMA; BACTERIAL INFECTION; BEHCET DISEASE; BLOOD DYSCRASIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; COMA; CONFUSION; CONGESTIVE CARDIOMYOPATHY; CONNECTIVE TISSUE DISEASE; CONSCIOUSNESS DISORDER; CONVULSION; CYSTIC FIBROSIS; DEEP VEIN THROMBOSIS; DEPRESSION; DERMATOLOGY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOCARDITIS; EOSINOPHILIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEVER; FIBROSIS; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEMATURIA; HEMOLYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS; HERPES SIMPLEX ENCEPHALITIS; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; INTRACRANIAL HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY SCAR; LETHARGY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOEFFLER PNEUMONIA; LUNG DISEASE; LYMPHADENOPATHY; MEGALOBLASTIC ANEMIA; MENTAL DEFICIENCY; MENTAL DISEASE; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREATITIS; PANCYTOPENIA; PAPILLEDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PROTEINURIA; PSYCHOSIS; QT PROLONGATION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RIGIDITY; SEIZURE; SIDE EFFECT; SINUS TACHYCARDIA; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STUPOR; SUDDEN DEATH; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UREMIA; URINE RETENTION; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

EID: 15744368600     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2004.06.013     Document Type: Article

References (166)

1. E. Orion, H. Matz, and V. Ruocco Parasitic skin infestation II, scabies, pediculosis, spider bites: unapproved treatments Clin. Dermatol. 20 2002 618 625
2. J. Kamgno, J. Gardon, and M. Boussinesq Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose Med. Trop. 60 2000 275 277
3. M. Boussinesq, J. Gardon, and N. Gardon-Wendel Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis Am. J. Trop. Med. Hyg. 58 1998 461 469
4. J. Gardon, N. Gardon-Wendel, and Demanga-Ngangue Serious reactions after mass treatment of onchocerciasis in an endemic area for Loa loa infection Lancet 350 1997 18 22
5. A. Rothova, A. van der Lelij, and J.S. Stilma Side-effects of ivermectin in treatment of onchocerciasis Lancet 1 1989 1439 1441
6. O. Cosidow Scabies and pediculosis Lancet 355 2000 819 826
7. R. Wolf, H. Matz, and E. Orion Dapsone Dermatol. Online J. 8 2002 2
8. M. Coleman Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention Toxicology 162 2001 53 60
9. P. Hornsten, M. Keisu, and B. Wilholm The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988 Arch. Dermatol. 126 1990 919 922
10. D. Jaffuel, B. Lebel, and D. Hillaire-Buys Eosinophilic pneumonia induced by dapsone BMJ 317 1998 181
11. J.D. Smilack, W.R. Wilson, and F.R. Cockerill III Tertracyclines, chloramphenicol, erythromycin, clindamycin, metronidazole Mayo Clin. Proc. 66 1991 1270 1280
12. F.J. Roe Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential Surgery 93 1983 158 164
13. C.K. Horlen, C.F. Seifert, and C.S. Malouf Toxic metronidazole-induced MRI changes Ann. Pharmacother. 34 2000 1273 1275
14. T.J. Halloran Convulsions associated with high cumulative doses of metronidazole Drug Intell. Clin. Pharm. 16 1982 409
15. Y. Belooseky, B. Grosman, and V. Marmelstein Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure Am. J. Med. Sci. 319 2000 338 339
16. J.J. Schentag, J.A. Ziemniak, and J.M. Greco Mental confusion in a patient treated with metronidazole-a concentration-related effect? Pharmacotherapy 2 1982 384 387
17. W. Schreiber, and J. Spernal Metronidazole-induced psychotic disorder Am. J. Psychiatry 154 1997 1170 1171
18. A.B. Omotoso, and O.G. Opadijo Acute encephalopathy associated with metronidazole therapy Afr. J. Med. Sci. 26 1997 97 98
19. E. Bjornsson, H. Nordlinder, and R. Olsson Metronidazole as a probable cause of severe liver injury Hepatogastroenterology 49 2002 252 254
20. W.A. Corey, B.N. Doebbeling, and K.J. DeJong Metronidazole-induced acute pancreatitis Rev. Infect. Dis. 13 1991 1213 1215
21. G.D. Friedman, and J.V. Selby How often does metronidazole induce pancreatitis? Gastroenterology 98 1990 1702 1703
22. M.E. Sura, K.A. Heinrich, and M. Suseno Metronidazole-associated pancreatitis Ann. Pharmacother. 34 2000 1152 1155
23. S.J. Cina, R.A. Russell, and S.E. Conradi Sudden death due to metronidazole/ethanol interaction Am. J. Forensic Med. Pathol. 17 1996 343 346
24. A. Bendesky, D. Menendez, and P. Ostrosky-Wegman Is metronidazole carcinogenic? Mutat. Res. 511 2002 133 144
25. H.R. Powell, P.M. Davidson, and D.A. McCredie Haemolytic-uremic syndrome after treatment with metronidazole Med. J. Aust. 149 1988 222 223
26. C.W. Weart, and L.C. Hyman Serum sickness associated with metronidazole South Med. J. 76 1983 410 411
27. R.S. Bedi Metronidazole-induced asthma Indian J. Chest Dis. Allied Sci. 33 1991 213 215
28. M. Kriestenson, and A. Fryden Pneumonitis caused by metronidazole JAMA 260 1988 184
29. C. Martin, A. Ruperti, and P. Saux Drug-induced agranulocytosis. Discussion of the responsibility of metronidazole Ann. Fr. Anesth. Reanim. 4 1985 521 523
30. A.K. Gupta, and N.H. Shear A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis Drug Saf. 22 2000 33 52
31. M.A. Jacobson, D.K. Hanks, and L.D. Ferrell Fatal acute hepatic necrosis due to fluconazole Am. J. Med. 96 1994 188 190
32. V. Novelli, and H. Holzel Safety and tolerability of fluconazole in children Antimicrob. Agents Chemother. 43 1999 1955 1960
33. D.A. Stevens, M. Diaz, and R. Negroni Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group Chemotherapy 43 1997 371 377
34. M.P. Guillaume, C. De Prez, and E. Cogan Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration Am. J. Gastroenterol. 91 1996 165 168
35. P. Munoz, S. Moreno, and J. Berenguer Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome Arch. Intern. Med. 151 1991 1020 1021
36. M. Khazan, and A.S. Mathis Probable case of torsades de pointes induced by fluconazole Pharmacotherapy 22 2002 1632 1637
37. V.N. Tholakanahalli, A. Potti, and J.F. Hanley Fluconazole-induced torsade de pointes Ann. Pharmacother. 35 2001 432 434
38. H. Murakami, H. Katahira, and T. Matsushima Agranulocytosis during treatment with fluconazole J. Int. Med. Res. 20 1992 492 494
39. A. Wong-Beringer, and K. Shriner Fluconazole-induced agranulocytosis with eosinophilia Pharmacotherapy 20 2000 484 486
40. S. Chuncharunee, B. Sathapatayavongs, and P. Singhasivanon Fluconazole-induced agranulocytosis Therapie 49 1994 517 518
41. A. Agarwal, V. Sakhuja, and K.S. Chugh Fluconazole-induced thrombocytopenia Ann. Intern. Med. 113 1990 899
42. A. Azon-Masoliver, and J. Vilaplana Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection Dermatology 187 1993 268 269
43. M. Abbott, D.L. Hughes, and R. Patel Angio-oedema after fluconazole Lancet 338 1991 633
44. G. Neuhaus, N. Pavic, and M. Pletscher Anaphylactic reaction after oral fluconazole BMJ 302 1991 1341
45. M.J. Gussenhoven, A. Haak, and J.D. Peereboom-Wynia Stevens-Johnson syndrome after fluconazole Lancet 338 1991 120
46. S.G. Albert, M.J. DeLeon, and A.B. Silverberg Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients Crit. Care Med. 29 2001 668 670
47. K. Matsumoto, K. Ueno, and H. Yohimura Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg/mL Ther. Drug Monit. 22 2000 635 636
48. R.M. Tucker, Y. Haq, and D.W. Denning Adverse events associated with itraconazole in 189 patients on chronic therapy J. Antimicrob. Chemother. 26 1990 561 566
49. A. Gupta, J. Lambert, and J. Revuz Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycosis Eur. J. Dermatol. 11 2001 6 10
50. H. Van Cauteren, A. Lampo, and J. Vandenberghe Toxicological profile and safety evaluation of antifungal azole derivatives Mycoses 32 1989 60 66
51. B.D. Brandbury, and S.S. Jick Itraconazole and fluconazole and certain rare, serious adverse events Pharmacotherapy 22 2002 697 700
52. A.K. Gupta, E. Chwetzoff, and J. Del Rosso Hepatic safety of itraconazole J. Cutan. Med. Surg. 6 2002 210 213
53. B. Adriaenssens, T. Roskams, and P. Steger Hepatotoxicity related to itraconazole: report of three cases Acta Clin. Belg. 56 2001 364 369
54. J.A. Tawalkar, R.E. Soetikno, and D.L. Carr-Locke Severe cholestasis related to itraconazole for treatment of onychomycosis Am. J. Gastroenterol. 94 1999 3632 3633
55. J.S. Parmar, T. Howell, and J. Kelly Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis Thorax 57 2002 749 750
56. R.J. Hay Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions J. Am. Acad. Dermatol. 29 1993 S50 S54
57. T. Yamamoto, K. Suzuki, and M. Yamakoshi A case of itraconazole-induced hypokalemia with pulmonary aspergilloma Kansenshogaku Zasshi 69 1995 1413 1417
58. M.R. Nelson, D. Smith, and D. Erskine Ventricular fibrillation secondary to itraconazole induced hypokalemia J. Infect. 26 1993 348
59. S.R. Ahmed, S.J. Singer, and B.G. Leissa Congestive heart failure associated with itraconazole Lancet 357 2001 1766 1767
60. A.M. Langers, and G.J. Jonkers Pancreatitis ascribed to the use of itraconazole Ned. Tijdsschr. Geneeskd. 145 2001 1127 1128
61. D. Mittal, and J. Wilkaitis Itraconazole-induced delirium Psychosomatics 44 2003 260 261
62. A.K. Gupta, J.Q. del Rosso, and C.W. Lynde Hepatitis associated with terbinafine therapy: three case reports and a review of the literature Clin. Exp. Dermatol. 23 1998 64 67
63. C. Ajit, A. Suvannasankha, and N. Zaeri Terbinafine-associated hepatotoxicity Am. J. Med. Sci. 325 2003 292 295
64. W.M. Chambers, A. Miller, and S. Jain Terbinafine-induced hepatic dysfunction Eur. J. Gastroenterol. Hepatol. 13 2001 1115 1118
65. K. Agarwal, D.M. Manas, and M. Hudson Terbinafine and fulminant hepatic failure N. Engl. J. Med. 340 1999 1292 1293
66. N.F. Fernandes, S.A. Geller, and T.L. Fong Terbinafine hepatotoxicity: case report and review of the literature Am. J. Gastroenterol. 93 1998 459 460
67. C. Aguilar, and A.K. Mueller Reversible agranulocytosis associated with oral terbinafine in a pediatric patient J. Am. Acad. Dermatol. 45 2001 632 634
68. A.K. Gupta, G.S. Soori, and J.Q. Del Rosso Severe neutropenia associated with oral terbinafine therapy J. Am. Acad. Dermatol. 38 1998 765 767
69. M. Da Conceicao, G. Genco, and J.C. Favier Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis Ann. Fr. Anesth. Reanim. 18 1999 996 999
70. A.F. Lawson, P.A. Green, and A.S. Brett A cute renal insufficiency due to oral acyclovir in a man with sickle cell trait South Med. J. 92 1999 1093 1094
71. M.A. Perazella Crystal-induced acute renal failure Am. J. Med. 106 1999 459 465
72. A.P. Blossom, J.D. Cleary, and W.P. Daley Acyclovir-induced crystalluria Ann. Pharmacother. 36 2002 526
73. M.E. Ernst, and R.J. Franey Acyclovir- and gancyclovir-induced neurotoxicity Ann. Pharmacother. 32 1998 111 113
74. S. Delerme, B. De Jonghe, and O. Proost Acyclovir-induced coma in a young patient without preexisting renal impairment Intensive Care Med. 28 2002 661 662
75. T. Vander, M. Medvedovsky, and Y. Herishanu Encephalopathy induced by oral acyclovir in a patient with normal renal function J. Infect. 46 2003 286
76. G.R. Rajan, J.P. Cobb, and C.K. Reiss Acyclovir induced coma in the intensive care unit Anaesth. Intensive Care 28 2000 305 307
77. J. Loughrey, P. Coleman, and J. Donohue Coma secondary to acyclovir neurotoxicity Ir. J. Med. Sci. 170 2001 69 70
78. H. Wolters, A. Mayer, and U. Gerhardt Hypotension in acyclovir therapy Schweiz. Rundsch. Med. Prax. 87 1998 1614 1618
79. H.M. Feder Jr., R.K. Goyal, and P.J. Krause Acyclovir-induced neutropenia in an infant with herpes simplex encephalitis Clin. Infect. Dis. 20 1995 1557 1559
80. B.A. Fazal, G.S. Turett, and J.E. Justman Stevens-Johnson syndrome induced by treatment with acyclovir Clin. Infect. Dis. 21 1995 1038 1039
81. E.P. Acosta, and C.V. Fletcher Valacyclovir Ann. Pharmacother. 31 1997 185 191
82. T. Okada, T. Nakao, and H. Matsumoto Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis Clin. Nephrol. 58 2002 168 170
83. H. Izzedine, L. Mercadal, and G. Aymard Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study Am. J. Nephrol. 21 2001 162 164
84. J.S. James Valacyclovir study stopped-worse survival AIDS Treat. News 17 1995 7 8
85. F.C. Koranda Antimalarials J. Am. Acad. Dermatol. 4 1981 650 655
86. J.S. Le Quintrec, and J.L. Le Quintrec Drug-induced myopathies Baillieres Clin. Rheumatol. 5 1991 21 38
87. M. Stein, M.J. Bell, and L.C. Ang Hydroxychloroquine neuromyotoxicity J. Rheumatol. 27 2000 2927 2931
88. D. Chernof, and K.S. Taylor Hydroxychloroquine-induced agranulocytosis Arch. Dermatol. 97 1968 163 164
89. L. Caminal Montero, A. Gonzalez Marroquin, and J. Ferro Mosquera Thrombocytopenia secondary to hydroxychloroquine Ann. Med. Interne 11 1994 310
90. A.J. Makin, J. Wendon, and S. Fitt Fulminant hepatic failure secondary to hydroxychloroquine Gut 35 1994 569 570
91. F.R. Ochsendorf, and U. Runne Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs Hautarzt 42 1991 140 146
92. K. Marquardt, and T.E. Albertson Treatment of hydroxychloroquine overdose Am. J. Emerg. Med. 19 2001 420 424
93. C.N. Ellis, and K.J. Krach Uses and complications of isotretinoin therapy J. Am. Acad. Dermatol. 45 2001 S150 S157
94. M. Jamshidi, R.J. Obermeyer, and S. Govindataj Acute pancreatitis secondary to isotretinoin-induced hyperlipidemia J. Okla. State Med. Assoc. 95 2002 79 80
95. T.L. McCarter, and Y.K. Chen Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy Am. J. Gastroenterol. 87 1992 1855 1858
96. P. Pavese, F. Kuentz, and C. Belleville Renal impairment induced by isotretinoin Nephrol. Dial. Transplant. 12 1997 1299
97. J.A.H. van Oers, J. de Leeuw, and E.F.H. van Bommel Nephrotic syndrome associated with isotretinoin Nephrol. Dial. Transplant. 15 2000 923 924
98. D.G. Jacobs, N.L. Deutsch, and M. Brewer Suicide, depression, and isotretinoin: is there a casual link? J. Am. Acad. Dermatol. 45 2001 S168 S175
99. K.A. O'Connell, J.K. Wilkin, and M. Pitts Isotretinoin (Accutane) and serious psychiatric adverse events J. Am. Acad. Dermatol. 48 2003 306 308
100. M.A. Trauner, and B.S. Ruben Isotretinoin induced rhabdomyolysis? A case report Dermatol. Online J. 5 1999 2
101. K. Charalabopoulos, V. Papalimmeou, and A. Charalabopoulos Two new adverse effects of isotretinoin Br. J. Dermatol. 148 2003 593
102. A. Vahlquist Long-term safety of retinoid therapy J. Am. Acad. Dermatol. 27 1992 S29 S33
103. A. Blum, C. Scherwitz, and G. Rassner Pseudoallergic hepatitis after a single intake of 10 mg acitretin (Neotigason) for treatment of psoriasis pustulosa Acta Derm. Venereol. 75 1995 332
104. C. Kreiss, S. Amin, and M.A. Nalesnik Severe cholestatic hepatitis in a patient taking acitretin Am. J. Gastroenterol. 97 2002 775 777
105. T.J. van Ditzhuijsen, U.J. van Haelst, and R.J. van Dooren-Greebe Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin) J. Hepatol. 11 1990 185 188
106. B. Royer, F. Ziegler, and P. Muret Acitretin-associated thrombotic stroke Ann. Pharmacother. 36 2002 1879 1882
107. C. Cuhadaroglu, D. Korular, and M. Erelel Respiratory distress with acitretin, reversal by corticosteroids Dermatol. Online J. 7 2001 5
108. R. Fleischmann, I. Iqbal, and P. Nandeshwar Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept Drug Saf. 25 2002 173 197
109. R.S. Larson, and M.S. Tallman Retinoic acid syndrome: manifestations, pathogenesis, and treatment Best Pract. Res. Clin. Haematol. 16 2003 453 461
110. T.R. Mikuls, and L.W. Moreland Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis Drug Saf. 16 2003 23 32
111. A.L. Kuijpers, and P.C. van de Kerkhof Risk-benefit assessment of methotrexate in the treatment of severe psoriasis Am. J. Clin. Dermatol. 1 2000 27 39
112. H.H. Roenigk Jr., R. Auerbach, and H. Maibach Methotrexate in psoriasis: consensus conference J. Am. Acad. Dermatol. 38 1998 478 485
113. D.A. Malatjalian, J.B. Ross, and C.N. Williams Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risk from obesity, diabetes and alcohol consumption during long-term follow-up Can. J. Gastroenterol. 10 1996 369 375
114. S.G. West Methotrexate hepatotoxicity Rheum. Dis. Clin. North Am. 23 1997 883 915
115. J.M. Berthelot, Y. Maugars, and M. Hamidou Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) Rev. Rheum. Engl. Ed. 62 1995 477 486
116. K.S. Kanik, and J.M. Cash Does methotrexate increase the risk of infection or malignancy? Rheum. Dis. Clin. North Am. 23 1997 955 967
117. H. Kono, S. Inokuma, and Y. Matsuzaki Two cases of methotrexate induced lymphomas in rheumatoid arthritis: an association with increased serum Ig E J. Rheumatol. 26 1999 2249 2253
118. A.C. Moseley, H.B. Lindsley, and B.S. Skikne Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease J. Rheumatol. 27 2000 810 813
119. L. Georgescu, and S.A. Paget Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf. 20 1999 475 487
120. J.M. Kremer Methotrexate update Scand. J. Rheumatol. 25 1996 341 344
121. P. Bohon, T. Dugernier, and J.C. Debongnie Hypersensitivity interstitial pneumopathy and ulcero-hemorrhagic rectocolitis: role of methotrexate Acta Gastroenterol. Belg. 56 1993 352 357
122. M.J. Van der Veen, J.J. Dekker, and H.J. Dinant Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis J. Rheumatol. 22 1995 1766 1768
123. F. Salaffi, P. Manganelli, and M. Carotti Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of 5 cases and review of the literature Clin. Rheumatol. 16 1997 296 304
124. G.W. Cannon Methotrexate pulmonary toxicity Rheum. Dis. Clin. North Am. 23 1997 917 937
125. U.F. Haustein, and M. Rytter Methotrexate in psoriasis: 26 years experience with low-dose long-term treatment J. Eur. Acad. Dermatol. Venereol. 14 2000 382 388
126. A. Shuper, B. Stark, and L. Kornereich Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia Isr. Med. Assoc. J. 4 2002 1050 1053
127. P.E. Kintzel Anticancer drug-induced kidney disorders Drug Saf. 24 2001 19 38
128. J.M. Berthelot, J. Glemarec, and A. Chiffoleau Treatment with low dose methotrexate in rheumatoid arthritis and risk factors for severe complications Therapie 52 1997 111 116
129. M.S. Doutre Ciclosporin Ann. Dermatol. Venereol. 129 2002 392 404
130. K.K. Lim, W.P. Su, and A.L. Schroeter Cyclosporine in the treatment of dermatologic disease: an update Mayo Clin. Proc. 71 1996 1182 1191
131. R.G. Woolfson, and G.H. Nelid Cyclosporin nephrotoxicity following cardiac transplantation Nephrol. Dial. Transplant. 12 1997 2054 2056
132. A.J. Olayei, A.M. de Mattos, and W.M. Bennett Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies Curr. Opin. Crit. Care 7 2001 384 389
133. M. Lassila Interaction of cyclosporine A and the rennin-angiotensin system: new perspectives Curr. Drug Metab. 3 2002 61 71
134. S.J. Taler, S.C. Textor, and V.J. Canzanello Cyclosporin-induced hypertension: incidence, pathogenesis and management Drug Saf. 20 1999 437 449
135. P.J. Medina, J.M. Sipols, and J.N. George Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Curr. Opin. Hematol. 8 2001 286 293
136. J.M. Gijtenbeek, M.J. van den Bent, and C.J. Vecht Cyclosporine neurotoxicity: a review J. Neurol. 246 1999 339 346
137. A.K. Shah Cyclosporine A neurotoxicity among bone marrow transplant recipients Clin. Neuropharmacol. 22 1999 67 73
138. J. Jeruss, S.V. Braun, and J.C. Reese Cyclosporine-induced white and grey matter central nervous system lesions in a pediatric renal transplant patient Pediatr. Transplant. 2 1998 45 50
139. S.L. McClure, J. Valentine, and K.B. Gordon Comparative tolerability of systemic treatments for plaque-type psoriasis Drug Saf. 25 2002 913 927
140. D.M. McMullan, B. Radovancevic, and C.M. Jackow Cutaneous T-cell lymphoma in a cardiac transplant recipient Tex. Heart Inst. J. 28 2001 203 207
141. A. Sayiner, T. Ece, and S. Duman Tuberculosis in renal transplant recipients Transplantation 68 1999 1268 1271
142. A.K. Ellis, and J.H. Day Second and third generation antihistamines in the treatment of urticaria Dermatol. Ther. 13 2000 327 336
143. C.M. Pratt, J. Mason, and T. Russell Cardiovascular safety of fexofenadine HCl Am. J. Cardiol. 83 1999 1451 1454
144. J. Mason, R. Reynolds, and N. Rao The systemic safety of fexofenadine HCl Clin. Exp. Allergy 29 1999 163 170
145. S. Jolles, J. Hughes, and S. Whittaker Dermatological uses of high-dose intravenous immunoglobulins Arch. Dermatol. 134 1998 80 86
146. M. Stangel, R. Kiefer, and M. Pette Side effects of intravenous immunoglobulins in neurological autoimmune disorders-a prospective study J. Neurol. 250 2003 818 821
147. T.H. Brannagan III, K.J. Nagle, and D.J. Lange Complications of intravenous immune globulin treatment in neurologic disease Neurology 47 1996 674 677
148. E.D. Crouch, and L.E. Watson Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura-a case report and literature review Angiology 53 2002 113 117
149. G.G. Emerson, C.N. Herndon, and A.G. Sreih Thrombotic complications after intravenous immunoglobulin therapy in two patients Pharmacotherapy 22 2002 1638 1641
150. K.A. Katz, C.M. Hivnor, and D.E. Geist Stroke and deep vein thrombosis complicating intravenous immunoglobulin infusions Arch. Dermatol. 139 2003 991 993
151. S. Gottlieb Intravenous immunoglobulin increases the risk of thrombotic events BMJ 324 2002 1056
152. F. Hayakawa, K. Imada, and M. Towatari Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin Br. J. Haematol. 118 2002 1187 1189
153. E. Grosshans, and G. Illy Thalidomide therapy for inflammatory dermatoses Int. J. Dermatol. 23 1984 598 602
154. A.J. Perri III, and S. Hsu A review of thalidomide's history and current dermatological applications Dermatol. Online J. 9 2003 5
155. S. Tseng, G. Pak, and K. Washenik Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses J. Am. Acad. Dermatol. 35 1996 969 979
156. D.I. Stirling Thalidomide and its impact in dermatology Semin. Cutan. Med. Surg. 174 1988 231 242
157. A. Kaur, S.S. Yu, and A.J. Lee Thalidomide-induced sinus bradycardia Ann. Pharmacother. 37 2003 1040 1043
158. E. Jonasch, and F.G. Haluska Interferon in oncological practice: review of interferon biology, clinical applications and toxicities Oncologist 6 2001 34 55
159. E.C. Borden, and D. Parkinson A perspective on the clinical effectiveness and tolerance of interferon-alpha Semin. Oncol. 25 1998 3 8
160. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernesoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J. Clin. Oncol. 14 1966 7 17
161. K. Weiss Safety profile of interferon-alfa therapy Semin. Oncol. 25 1998 9 13
162. A.D. Valentine, C.A. Meyers, and M.A. Kling Mood and cognitive side effects of interferon alfa therapy Semin. Oncol. 25 1998 39 47
163. W.E. Nolten, D. Goldstein, and M. Lindstrom Effects of cytokines on the pituitary-adrenal axis in cancer patients J. Interferon Res. 13 1993 349 357
164. M. Schafer, and M. Schwaiger Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects Fortschr. Neuro. Psychiatr. 71 2003 469 476
165. S.D. Li, S. Yong, and D. Srinivas Reactivation of sarcoidosis during interferon therapy J. Gastroenterol. 37 2002 50 54
166. P. Raanani, and I. Ben-Bassat Immune-mediated complications during interferon therapy in hematological patients Acta Haematol. 107 2002 133 144